REVIEW

Finding biomarkers for non-small cell lung cancer diagnosis and prognosis

  • Tian XIAO 1 ,
  • Lei BAO , 2 ,
  • Hongbin JI , 1
Expand
  • 1. State Key Laboratory of Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China
  • 2. Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA

Received date: 18 May 2011

Accepted date: 24 Jun 2011

Published date: 01 Feb 2012

Copyright

2014 Higher Education Press and Springer-Verlag Berlin Heidelberg

Abstract

Despite of several decades of efforts, lung cancer remains one of most deadly diseases, with a 5-year survival rate approximately 15% worldwide. In China, the situation is even worse. Although there is no official data released yet, the 5-year survival rate is estimated to be around 10%. In past 30 years, there was a dramatic increase of lung cancer related death about 465% in mainland China. Annually, about 400000 people die of lung cancer and the number is still climbing. At the same time, the number of new lung cancer cases also increase rapidly. The high mortality of lung cancer is mainly ascribed to two factors: the lack of effective ways to identify early diagnostic biomarkers and to treat metastatic cancer. Lung cancer can be pathologically divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), among which NSCLC accounts for about 80% of all cases. In this review, we will focus on the recent efforts and progress in finding biomarkers in NSCLC. Since biomarkers are derived from both invasive and non-invasive ways, we divide them into these two categories and review them separately. We hope the discovery of biomarkers will eventually change the current clinical practice in NSCLC patients and improve their quality of life.

Cite this article

Tian XIAO , Lei BAO , Hongbin JI . Finding biomarkers for non-small cell lung cancer diagnosis and prognosis[J]. Frontiers in Biology, 2012 , 7(1) : 14 -23 . DOI: 10.1007/s11515-011-1163-1

Acknowledgements

This work was supported by the National Basic Research Program of China (No. 2010CB912102), the National Natural Science Foundation of China (Grant Nos.30871284 and 30971461), the Chinese Academy of Sciences (No. 2010KIP504), and the Science and Technology Commission of Shanghai Municipality (No. 09JC1416300). H. J. is a scholar of the Hundred Talents Program of the Chinese Academy of Sciences.
1
Amos C I, Wu X, Broderick P, Gorlov I P, Gu J, Eisen T, Dong Q, Zhang Q, Gu X, Vijayakrishnan J, Sullivan K, Matakidou A, Wang Y, Mills G, Doheny K, Tsai Y Y, Chen W V, Shete S, Spitz M R, Houlston R S (2008). Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet, 40(5): 616-622

DOI PMID

2
Angelopoulou K, Diamandis E P, Sutherland D J, Kellen J A, Bunting P S (1994). Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer, 58(4): 480-487

DOI PMID

3
Aruga A, Koizumi M, Hotta R, Takahashi S, Ogata E (1997). Usefulness of bone metabolic markers in the diagnosis and follow-up of bone metastasis from lung cancer. Br J Cancer, 76(6): 760-764

DOI PMID

4
Ayesh R, Idle J R, Ritchie J C, Crothers M J, Hetzel M R (1984). Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature, 312(5990): 169-170

DOI PMID

5
Baron A T, Wilken J A, Haggstrom D E, Goodrich S T, Maihle N J (2009). Clinical implementation of soluble EGFR (sEGFR) as a theragnostic serum biomarker of breast, lung and ovarian cancer. IDrugs, 12(5): 302-308

PMID

6
Bass A J, Watanabe H, Mermel C H, Yu S, Perner S, Verhaak R G, Kim S Y, Wardwell L, Tamayo P, Gat-Viks I, Ramos A H, Woo M S, Weir B A, Getz G, Beroukhim R, O’Kelly M, Dutt A, Rozenblatt-Rosen O, Dziunycz P, Komisarof J, Chirieac L R, Lafargue C J, Scheble V, Wilbertz T, Ma C, Rao S, Nakagawa H, Stairs D B, Lin L, Giordano T J, Wagner P, Minna J D, Gazdar A F, Zhu C Q, Brose M S, Cecconello I, Jr U R, Marie S K, Dahl O, Shivdasani R A, Tsao M S, Rubin M A, Wong K K, Regev A, Hahn W C, Beer D G, Rustgi A K, Meyerson M (2009). SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet, 41(11): 1238-1242

DOI PMID

7
Bates J, Rutherford R, Divilly M, Finn J, Grimes H, O’Muircheartaigh I, Gilmartin J J (1997). Clinical value of CYFRA 21.1, carcinoembryonic antigen, neurone-specific enolase, tissue polypeptide specific antigen and tissue polypeptide antigen in the diagnosis of lung cancer. Eur Respir J, 10(11): 2535-2538

DOI PMID

8
Baty F, Facompré M, Kaiser S, Schumacher M, Pless M, Bubendorf L, Savic S, Marrer E, Budach W, Buess M, Kehren J, Tamm M, Brutsche M H (2010). Gene profiling of clinical routine biopsies and prediction of survival in non-small cell lung cancer. Am J Respir Crit Care Med, 181(2): 181-188

DOI PMID

9
Beer D G, Kardia S L, Huang C C, Giordano T J, Levin A M, Misek D E, Lin L, Chen G, Gharib T G, Thomas D G, Lizyness M L, Kuick R, Hayasaka S, Taylor J M, Iannettoni M D, Orringer M B, Hanash S (2002). Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med, 8(8): 816-824

PMID

10
Berger A H, Niki M, Morotti A, Taylor B S, Socci N D, Viale A, Brennan C, Szoke J, Motoi N, Rothman P B, Teruya-Feldstein J, Gerald W L, Ladanyi M, Pandolfi P P (2010). Identification of DOK genes as lung tumor suppressors. Nat Genet, 42(3): 216-223

DOI PMID

11
Bhattacharjee A, Richards W G, Staunton J, Li C, Monti S, Vasa P, Ladd C, Beheshti J, Bueno R, Gillette M, Loda M, Weber G, Mark E J, Lander E S, Wong W, Johnson B E, Golub T R, Sugarbaker D J, Meyerson M (2001). Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA, 98(24): 13790-13795

DOI PMID

12
Borgia J A, Basu S, Faber L P, Kim A W, Coon J S, Kaiser-Walters K A, Fhied C, Thomas S, Rouhi O, Warren W H, Bonomi P, Liptay M J (2009). Establishment of a multi-analyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer. J Thorac Oncol, 4(3): 338-347

DOI PMID

13
Brandt-Rauf P W, Smith S, Hemminki K, Koskinen H, Vainio H, Niman H, Ford J (1992). Serum oncoproteins and growth factors in asbestosis and silicosis patients. Int J Cancer, 50(6): 881-885

DOI PMID

14
Bremnes R M, Sirera R, Camps C (2005). Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up? Lung Cancer, 49(1): 1-12

DOI PMID

15
Caporaso N E, Tucker M A, Hoover R N, Hayes R B, Pickle L W, Issaq H J, Muschik G M, Green-Gallo L, Buivys D, Aisner S, Resau J H, Trump B F, Tollerud D, Weston A, Harris C C (1990). Lung cancer and the debrisoquine metabolic phenotype. J Natl Cancer Inst, 82(15): 1264-1272

DOI PMID

16
Carrola J, Rocha C M, Barros A S, Gil A M, Goodfellow B J, Carreira I M, Bernardo J, Gomes A, Sousa V, Carvalho L, Duarte I F (2011). Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of urine. J Proteome Res, 10(1): 221-230

DOI PMID

17
Castillo S D, Angulo B, Suarez-Gauthier A, Melchor L, Medina P P, Sanchez-Verde L, Torres-Lanzas J, Pita G, Benitez J, Sanchez-Cespedes M (2010). Gene amplification of the transcription factor DP1 and CTNND1 in human lung cancer. J Pathol, 222(1): 89-98

PMID

18
Chen H Y, Yu S L, Chen C H, Chang G C, Chen C Y, Yuan A, Cheng C L, Wang C H, Terng H J, Kao S F, Chan W K, Li H N, Liu C C, Singh S, Chen W J, Chen J J, Yang P C (2007). A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med, 356(1): 11-20

DOI PMID

19
Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Wang J, Zen K, Zhang J, Zhang C Y (2008). Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res, 18(10): 997-1006

DOI PMID

20
Chen X, Hu Z, Wang W, Ba Y, Ma L, Zhang C, Wang C, Ren Z, Zhao Y, Wu S,Zhuang R, Zhang Y, Hu H, Liu C, Xu L, Wang J, Shen H, Zhang J, Zen K, Zhang C Y (2011). Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel non-invasive biomarkers for non-small cell lung cancer diagnosis. Int J Cancer,

DOI

21
Cheng T L, Chang M Y, Huang S Y, Sheu C C, Kao E L, Cheng Y J, Chong I W (2005). Overexpression of circulating c-met messenger RNA is significantly correlated with nodal stage and early recurrence in non-small cell lung cancer. Chest, 128(3): 1453-1460

DOI PMID

22
Chitale D, Gong Y, Taylor B S, Broderick S, Brennan C, Somwar R, Golas B, Wang L, Motoi N, Szoke J, Reinersman J M, Major J, Sander C, Seshan V E, Zakowski M F, Rusch V, Pao W, Gerald W, Ladanyi M (2009). An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Oncogene, 28(31): 2773-2783

DOI PMID

23
Chung C C, Magalhaes W C, Gonzalez-Bosquet J, Chanock S J (2010). Genome-wide association studies in cancer—current and future directions. Carcinogenesis, 31(1): 111-120

DOI PMID

24
Chung J H, Park M S, Kim Y S, Chang J, Kim J H, Kim S K, Kim S K (2005). Usefulness of bone metabolic markers in the diagnosis of bone metastasis from lung cancer. Yonsei Med J, 46(3): 388-393

DOI PMID

25
Duche J C, Joanne C, Barre J, de Cremoux H, Dalphin J C, Depierre A, Brochard P, Tillement J P, Bechtel P (1991). Lack of a relationship between the polymorphism of debrisoquine oxidation and lung cancer. Br J Clin Pharmacol, 31(5): 533-536

PMID

26
Egloff A M, Weissfeld J, Land S R, Finn O J (2005). Evaluation of anticyclin B1 serum antibody as a diagnostic and prognostic biomarker for lung cancer. Ann N Y Acad Sci, 1062(1): 29-40

DOI PMID

27
Endoh H, Tomida S, Yatabe Y, Konishi H, Osada H, Tajima K, Kuwano H, Takahashi T, Mitsudomi T (2004). Prognostic model of pulmonary adenocarcinoma by expression profiling of eight genes as determined by quantitative real-time reverse transcriptase polymerase chain reaction. J Clin Oncol, 22(5): 811-819

DOI PMID

28
Fleischhacker M, Beinert T, Ermitsch M, Seferi D, Possinger K, Engelmann C, Jandrig B (2001). Detection of amplifiable messenger RNA in the serum of patients with lung cancer. Ann N Y Acad Sci, 945(1): 179-188

DOI PMID

29
Foss K M, Sima C, Ugolini D, Neri M, Allen K E, Weiss G J (2011). miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer. J Thorac Oncol, 6(3): 482-488

DOI PMID

30
Gallegos Ruiz M I, Floor K, Roepman P, Rodriguez J A, Meijer G A, Mooi W J, Jassem E, Niklinski J, Muley T, van Zandwijk N, Smit E F, Beebe K, Neckers L, Ylstra B, Giaccone G (2008). Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target. PLoS ONE, 3(3): e0001722

DOI PMID

31
Galvan A, Falvella F S, Frullanti E, Spinola M, Incarbone M, Nosotti M, Santambrogio L, Conti B, Pastorino U, Gonzalez-Neira A, Dragani T A (2010). Genome-wide association study in discordant sibships identifies multiple inherited susceptibility alleles linked to lung cancer. Carcinogenesis, 31(3): 462-465

DOI PMID

32
Gao Y, Xiao Q, Ma H, Li L, Liu J, Feng Y, Fang Z, Wu J, Han X, Zhang J, Sun Y, Wu G, Padera R, Chen H, Wong K K, Ge G, Ji H (2010). LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling. Proc Natl Acad Sci USA, 107(44): 18892-18897

DOI PMID

33
Garber M E, Troyanskaya O G, Schluens K, Petersen S, Thaesler Z, Pacyna-Gengelbach M, van de Rijn M, Rosen G D, Perou C M, Whyte R I, Altman R B, Brown P O, Botstein D, Petersen I (2001). Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci USA, 98(24): 13784-13789

DOI PMID

34
Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N, Benjamin H, Kushnir M, Cholakh H, Melamed N, Bentwich Z, Hod M, Goren Y, Chajut A (2008). Serum microRNAs are promising novel biomarkers. PLoS ONE, 3(9): e3148

DOI PMID

35
Giovanella L, Ceriani L, Bandera M, Rimoldi R, Beghé B, Roncari G (1995). Tissue polypeptide specific antigen (tps) and cytokeratin 19 fragment (CYFRA 21.1) immunoradiometric assay in non small cell lung cancer evaluation. Q J Nucl Med, 39(4): 285-289

PMID

36
He L, He X, Lim L P, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, Jackson A L, Linsley P S, Chen C, Lowe S W, Cleary M A, Hannon G J (2007). A microRNA component of the p53 tumour suppressor network. Nature, 447(7148): 1130-1134

DOI PMID

37
Helmig S, Schneider J (2007). Oncogene and tumor-suppressor gene products as serum biomarkers in occupational-derived lung cancer. Expert Rev Mol Diagn, 7(5): 555-568

DOI PMID

38
Hoagland L F IV, Campa M J, Gottlin E B, Herndon J E 2nd, Patz E F Jr (2007). Haptoglobin and posttranslational glycan-modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer. Cancer, 110(10): 2260-2268

DOI PMID

39
Hsiung C A, Lan Q, Hong Y C, Chen C J, Hosgood H D, Chang I S, Chatterjee N, Brennan P, Wu C, Zheng W, Chang G C, Wu T, Park J Y, Hsiao C F, Kim Y H, Shen H, Seow A, Yeager M, Tsai Y H, Kim Y T, Chow W H, Guo H, Wang W C, Sung S W, Hu Z, Chen K Y, Kim J H, Chen Y, Huang L, Lee K M, Lo Y L, Gao Y T, Kim J H, Liu L, Huang M S, Jung T H, Jin G, Caporaso N, Yu D, Kim C H, Su W C, Shu X O, Xu P, Kim I S, Chen Y M, Ma H, Shen M, Cha S I, Tan W, Chang C H, Sung J S, Zhang M, Yang T Y, Park K H, Yuenger J, Wang C L, Ryu J S, Xiang Y, Deng Q, Hutchinson A, Kim J S, Cai Q, Landi M T, Yu C J, Park J Y, Tucker M, Hung J Y, Lin C C, Perng R P, Boffetta P, Chen C Y, Chen K C, Yang S Y, Hu C Y, Chang C K, Fraumeni J F Jr, Chanock S, Yang P C, Rothman N, Lin D (2010). The 5p15.33 locus is associated with risk of lung adenocarcinoma in never-smoking females in Asia. PLoS Genet, 6(8): e1001051

DOI PMID

40
Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, Chen Y, Xu L, Zen K, Zhang C, Shen H (2010). Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol, 28(10): 1721-1726

DOI PMID

41
Huang Y T, Heist R S, Chirieac L R, Lin X, Skaug V, Zienolddiny S, Haugen A, Wu M C, Wang Z, Su L, Asomaning K, Christiani D C (2009). Genome-wide analysis of survival in early-stage non-small-cell lung cancer. J Clin Oncol, 27(16): 2660-2667

DOI PMID

42
Hung R J, Christiani D C, Risch A, Popanda O, Haugen A, Zienolddiny S, Benhamou S, Bouchardy C, Lan Q, Spitz M R, Wichmann H E, LeMarchand L, Vineis P, Matullo G, Kiyohara C, Zhang Z F, Pezeshki B, Harris C, Mechanic L, Seow A, Ng D P, Szeszenia-Dabrowska N, Zaridze D, Lissowska J, Rudnai P, Fabianova E, Mates D, Foretova L, Janout V, Bencko V, Caporaso N, Chen C, Duell E J, Goodman G, Field J K, Houlston R S, Hong Y C, Landi M T, Lazarus P, Muscat J, McLaughlin J, Schwartz A G, Shen H, Stucker I, Tajima K, Matsuo K, Thun M, Yang P, Wiencke J, Andrew A S, Monnier S, Boffetta P, Brennan P (2008a). International Lung Cancer Consortium: pooled analysis of sequence variants in DNA repair and cell cycle pathways. Cancer Epidemiol Biomarkers Prev, 17(11): 3081-3089

DOI PMID

43
Hung R J, McKay J D, Gaborieau V, Boffetta P, Hashibe M, Zaridze D, Mukeria A, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Mates D, Bencko V, Foretova L, Janout V, Chen C, Goodman G, Field J K, Liloglou T, Xinarianos G, Cassidy A, McLaughlin J, Liu G, Narod S, Krokan H E, Skorpen F, Elvestad M B, Hveem K, Vatten L, Linseisen J, Clavel-Chapelon F, Vineis P, Bueno-de-Mesquita H B, Lund E, Martinez C, Bingham S, Rasmuson T, Hainaut P, Riboli E, Ahrens W, Benhamou S, Lagiou P, Trichopoulos D, Holcátová I, Merletti F, Kjaerheim K, Agudo A, Macfarlane G, Talamini R, Simonato L, Lowry R, Conway D I, Znaor A, Healy C, Zelenika D, Boland A, Delepine M, Foglio M, Lechner D, Matsuda F, Blanche H, Gut I, Heath S, Lathrop M, Brennan P (2008b). A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature, 452(7187): 633-637

DOI PMID

44
Jagadeeswaran R, Surawska H, Krishnaswamy S, Janamanchi V, Mackinnon A C, Seiwert T Y, Loganathan S, Kanteti R, Reichman T, Nallasura V, Schwartz S, Faoro L, Wang Y C, Girard L, Tretiakova M S, Ahmed S, Zumba O, Soulii L, Bindokas V P, Szeto L L, Gordon G J, Bueno R, Sugarbaker D, Lingen M W, Sattler M, Krausz T, Vigneswaran W, Natarajan V, Minna J, Vokes E E, Ferguson M K, Husain A N, Salgia R (2008). Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. Cancer Res, 68(1): 132-142

DOI PMID

45
Johnson S M, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert K L, Brown D, Slack F J (2005). RAS is regulated by the let-7 microRNA family. Cell, 120(5): 635-647

DOI PMID

46
Kang J U, Koo S H, Kwon K C, Park J W (2010). Frequent silence of chromosome 9p, homozygous DOCK8, DMRT1 and DMRT3 deletion at 9p24.3 in squamous cell carcinoma of the lung. Int J Oncol, 37(2): 327-335

PMID

47
Kopreski M S, Benko F A, Gocke C D (2001). Circulating RNA as a tumor marker: detection of 5T4 mRNA in breast and lung cancer patient serum. Ann N Y Acad Sci, 945(1): 172-178

DOI PMID

48
Krolikowski F J, Reuter K, Waalkes T P, Sieber S M, Adamson R H (1976). Serum sialic acid levels in lung cancer patients. Pharmacology, 14(1): 47-51

DOI PMID

49
Kumar M S, Pester R E, Chen C Y, Lane K, Chin C, Lu J, Kirsch D G, Golub T R, Jacks T (2009). Dicer1 functions as a haploinsufficient tumor suppressor. Genes Dev, 23(23): 2700-2704

DOI PMID

50
Lawrie C H, Gal S, Dunlop H M, Pushkaran B, Liggins A P, Pulford K, Banham A H, Pezzella F, Boultwood J, Wainscoat J S, Hatton C S, Harris A L (2008). Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol, 141(5): 672-675

DOI PMID

51
Li D, Shimamura T, Ji H, Chen L, Haringsma H J, McNamara K, Liang M C, Perera S A, Zaghlul S, Borgman C L, Kubo S, Takahashi M, Sun Y, Chirieac L R, Padera R F, Lindeman N I, Jänne P A, Thomas R K, Meyerson M L, Eck M J, Engelman J A, Shapiro G I, Wong K K (2007). Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell, 12(1): 81-93

DOI PMID

52
Li Y, Sheu C C, Ye Y, de Andrade M, Wang L, Chang S C, Aubry M C, Aakre J A, Allen M S, Chen F, Cunningham J M, Deschamps C, Jiang R, Lin J, Marks R S, Pankratz V S, Su L, Li Y, Sun Z, Tang H, Vasmatzis G, Harris C C, Spitz M R, Jen J, Wang R, Zhang Z F, Christiani D C, Wu X, Yang P (2010). Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol, 11(4): 321-330

DOI PMID

53
Liu L, Sun S, Liu J, Wu S, Dai S, Wang X, Huang L, Xiao X, He D (2009). A new serum biomarker for lung cancer-transthyretin. J Lung Cancer, 12(4): 300-305

PMID

54
Luo J C, Zehab R, Anttila S, Ridanpaa M, Husgafvel-Pursiainen K, Vainio H, Carney W, De Vivo I, Milling C, Brandt-Rauf P W (1994). Detection of serum p53 protein in lung cancer patients. J Occup Med, 36(2): 155-160

DOI PMID

55
Ma C, Quesnelle K M, Sparano A, Rao S, Park M S, Cohen M A, Wang Y, Samanta M, Kumar M S, Aziz M U, Naylor T L, Weber B L, Fakharzadeh S S, Weinstein G S, Vachani A, Feldman M D, Brose M S (2009). Characterization CSMD1 in a large set of primary lung, head and neck, breast and skin cancer tissues. Cancer Biol Ther, 8(10): 907-916

DOI PMID

56
McCaughan F, Pole J C, Bankier A T, Konfortov B A, Carroll B, Falzon M, Rabbitts T H, George P J, Dear P H, Rabbitts P H (2010). Progressive 3q amplification consistently targets SOX2 in preinvasive squamous lung cancer. Am J Respir Crit Care Med, 182(1): 83-91

DOI PMID

57
McKay J D, Hung R J, Gaborieau V, Boffetta P, Chabrier A, Byrnes G, Zaridze D, Mukeria A, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Mates D, Bencko V, Foretova L, Janout V, McLaughlin J, Shepherd F, Montpetit A, Narod S, Krokan H E, Skorpen F, Elvestad M B, Vatten L, Njølstad I, Axelsson T, Chen C, Goodman G, Barnett M, Loomis M M, Lubiñski J, Matyjasik J, Lener M, Oszutowska D, Field J, Liloglou T, Xinarianos G, Cassidy A, Vineis P, Clavel-Chapelon F, Palli D, Tumino R, Krogh V, Panico S, González C A, Ramón Quirós J, Martínez C, Navarro C, Ardanaz E, Larrañaga N, Kham K T, Key T, Bueno-de-Mesquita H B, Peeters P H, Trichopoulou A, Linseisen J, Boeing H, Hallmans G, Overvad K, Tjønneland A, Kumle M, Riboli E, Zelenika D, Boland A, Delepine M, Foglio M, Lechner D, Matsuda F, Blanche H, Gut I, Heath S, Lathrop M, Brennan P, the EPIC Study (2008). Lung cancer susceptibility locus at 5p15.33. Nat Genet, 40(12): 1404-1406

DOI PMID

58
Medina P P, Castillo S D, Blanco S, Sanz-Garcia M, Largo C, Alvarez S, Yokota J, Gonzalez-Neira A, Benitez J, Clevers H C, Cigudosa J C, Lazo P A, Sanchez-Cespedes M (2009). The SRY-HMG box gene, SOX4, is a target of gene amplification at chromosome 6p in lung cancer. Hum Mol Genet, 18(7): 1343-1352

DOI PMID

59
Miki D, Kubo M, Takahashi A, Yoon K A, Kim J, Lee G K, Zo J I, Lee J S, Hosono N, Morizono T, Tsunoda T, Kamatani N, Chayama K, Takahashi T, Inazawa J, Nakamura Y, Daigo Y (2010). Variation in TP63 is associated with lung adenocarcinoma susceptibility in Japanese and Korean populations. Nat Genet, 42(10): 893-896

DOI PMID

60
Mitchell P S, Parkin R K, Kroh E M, Fritz B R, Wyman S K, Pogosova-Agadjanyan E L, Peterson A, Noteboom J, O’Briant K C, Allen A, Lin D W, Urban N, Drescher C W, Knudsen B S, Stirewalt D L, Gentleman R, Vessella R L, Nelson P S, Martin D B, Tewari M (2008). Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA, 105(30): 10513-10518

DOI PMID

61
Miura N, Nakamura H, Sato R, Tsukamoto T, Harada T, Takahashi S, Adachi Y, Shomori K, Sano A, Kishimoto Y, Ito H, Hasegawa J, Shiota G (2006). Clinical usefulness of serum telomerase reverse transcriptase (hTERT) mRNA and epidermal growth factor receptor (EGFR) mRNA as a novel tumor marker for lung cancer. Cancer Sci, 97(12): 1366-1373

DOI PMID

62
Newnham G M, Thomas D M, McLachlan S A, Wright G, Conron M (2008). Molecular profiling of non-small cell lung cancer: of what value in clinical practice? Heart Lung Circ, 17(6): 451-462

DOI PMID

63
Patel K, Farlow E C, Kim A W, Lee B S, Basu S, Coon J S, Decresce D, Thimothy L, Walters K A, Fhied C, Chang C, Chen S H, Faber L P, Bonomi P, Liptay M J, Borgia J A(2011). Enhancement of a multianalyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer with circulating autoantibody biomarkers. Int J Cancer, 129(1): 133-142

64
Patz E F Jr, Campa M J, Gottlin E B, Kusmartseva I, Guan X R, Herndon J E II (2007). Panel of serum biomarkers for the diagnosis of lung cancer. J Clin Oncol, 25(35): 5578-5583

DOI PMID

65
Petty R D, Nicolson M C, Kerr K M, Collie-Duguid E, Murray G I (2004). Gene expression profiling in non-small cell lung cancer: from molecular mechanisms to clinical application. Clin Cancer Res, 10(10): 3237-3248

DOI PMID

66
Potti A, Mukherjee S, Petersen R, Dressman H K, Bild A, Koontz J, Kratzke R, Watson M A, Kelley M, Ginsburg G S, West M, Harpole D H Jr, Nevins J R (2006). A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med, 355(6): 570-580

DOI PMID

67
Pujol J L, Cooper E H, Grenier J, Purves D A, Lehmann M, Ray P, Aouta M D, Bashir M, Godard P, Michel F B (1994). Clinical evaluation of serum tissue polypeptide-specific antigen (TPS) in non-small cell lung cancer. Eur J Cancer, 30A(12): 1768-1774

DOI PMID

68
Rodríguez-Piñeiro A M, Blanco-Prieto S, Sánchez-Otero N, Rodríguez-Berrocal F J, de la Cadena M P (2010). On the identification of biomarkers for non-small cell lung cancer in serum and pleural effusion. J Proteomics, 73(8): 1511-1522

DOI PMID

69
Rokicki M, Rokicki W, Czyzewski K, Wojcieszek E (1987). Usefulness of determining the levels of sialic acid in the blood serum, pulmonary homogenates and urine of patients with lung cancer. Nowotwory, 37(3): 226-231

PMID

70
Salvati F, Antilli A, Cruciani A R, Pau F, Flore F, Munno R, De Angelis G, Cipri A, Pigorini F (1985). Plasma carcinoembryonic antigen and tissue polypeptide antigen levels in lung cancer: correlation with cell types and stage. Cancer Detect Prev, 8(1-2): 111-114

PMID

71
Sanchez-Palencia A, Gomez-Morales M, Gomez-Capilla J A, Pedraza V, Boyero L, Rosell R, Farez-Vidal M E (2011). Gene expression profiling reveals novel biomarkers in nonsmall cell lung cancer. Int J Cancer, 129(2): 355-364

72
Sato Y, Yamamoto N, Kunitoh H, Ohe Y, Minami H, Laird N M, Katori N, Saito Y, Ohnami S, Sakamoto H, Sawada J, Saijo N, Yoshida T, Tamura T (2011). Genome-wide association study on overall survival of advanced non-small cell lung cancer patients treated with carboplatin and paclitaxel. J Thorac Oncol, 6(1): 132-138

DOI PMID

73
Sen E, Ulger F, Kaya A, Akar N, Gonullu U (2008). Serum endothelial monocyte-activating polypeptide-II: a novel biomarker in patients with non-small-cell lung cancer. Clin Lung Cancer, 9(3): 166-170

DOI PMID

74
Shaw G L, Falk R T, Deslauriers J, Frame J N, Nesbitt J C, Pass H I, Issaq H J, Hoover R N, Tucker M A (1995). Debrisoquine metabolism and lung cancer risk. Cancer Epidemiol Biomarkers Prev, 4(1): 41-48

PMID

75
Shedden K, Taylor J M, Enkemann S A, Tsao M S, Yeatman T J, Gerald W L, Eschrich S, Jurisica I, Giordano T J, Misek D E, Chang A C, Zhu C Q, Strumpf D, Hanash S, Shepherd F A, Ding K, Seymour L, Naoki K, Pennell N, Weir B, Verhaak R, Ladd-Acosta C, Golub T, Gruidl M, Sharma A, Szoke J, Zakowski M, Rusch V, Kris M, Viale A, Motoi N, Travis W, Conley B, Seshan V E, Meyerson M, Kuick R, Dobbin K K, Lively T, Jacobson J W, Beer D G, Shedden K, Taylor J M G, Enkemann S A, Tsao M S, Yeatman T J, Gerald W L, Eschrich S, Jurisica I, Giordano T J, Misek D E, Chang A C, Zhu C Q, Strumpf D, Hanash S, Shepherd F A, Ding K, Seymour L, Naoki K, Pennell N, Weir B, Verhaak R, Ladd-Acosta C, Golub T, Gruidl M, Sharma A, Szoke J, Zakowski M, Rusch V, Kris M, Viale A, Motoi N, Travis W, Conley B, Seshan V E, Meyerson M, Kuick R, Dobbin K K, Lively T, Jacobson J W, Beer D G, he Director’s Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma (2008). Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med, 14(8): 822-827

DOI PMID

76
Smirnova K D, Lazarev N I (1970). Adrenal cortex steroid hormone metabolites in the urine of patients with cancer of the lung. Vestn Akad Med Nauk SSSR, 25(2): 35-38

PMID

77
Speirs C J, Murray S, Davies D S, Biola Mabadeje A F, Boobis A R (1990). Debrisoquine oxidation phenotype and susceptibility to lung cancer. Br J Clin Pharmacol, 29(1): 101-109

PMID

78
Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y, Mitsudomi T, Takahashi T (2004). Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res, 64(11): 3753-3756

DOI PMID

79
Thöm I, Andritzky B, Schuch G, Burkholder I, Edler L, Johansen J S, Bokemeyer C, Schumacher U, Laack E (2010). Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer. Cancer, 116(17): 4114-4121

DOI PMID

80
Toschi L, Cappuzzo F (2010). Clinical implications of MET gene copy number in lung cancer. Future Oncol, 6(2): 239-247

DOI PMID

81
Ulivi P, Mercatali L, Zoli W, Dell’amore D, Poletti V, Casoni G L, Scarpi E, Flamini E, Amadori D, Silvestrini R (2008). Serum free DNA and COX-2 mRNA expression in peripheral blood for lung cancer detection. Thorax, 63(9): 843-844

DOI PMID

82
Vollebergh M A, Kappers I, Klomp H M, Buning-Kager J C, Korse C M, Hauptmann M, de Visser K E, van den Heuvel M M, Linn S C (2010). Ligands of epidermal growth factor receptor and the insulin-like growth factor family as serum biomarkers for response to epidermal growth factor receptor inhibitors in patients with advanced non-small cell lung cancer. J Thorac Oncol, 5(12): 1939-1948

DOI PMID

83
Wang Y, Broderick P, Webb E, Wu X, Vijayakrishnan J, Matakidou A, Qureshi M, Dong Q, Gu X, Chen W V, Spitz M R, Eisen T, Amos C I, Houlston R S (2008). Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat Genet, 40(12): 1407-1409

DOI PMID

84
Weir B A, Woo M S, Getz G, Perner S, Ding L, Beroukhim R, Lin W M, Province M A, Kraja A, Johnson L A, Shah K, Sato M, Thomas R K, Barletta J A, Borecki I B, Broderick S, Chang A C, Chiang D Y, Chirieac L R, Cho J, Fujii Y, Gazdar A F, Giordano T, Greulich H, Hanna M, Johnson B E, Kris M G, Lash A, Lin L, Lindeman N, Mardis E R, McPherson J D, Minna J D, Morgan M B, Nadel M, Orringer M B, Osborne J R, Ozenberger B, Ramos A H, Robinson J, Roth J A, Rusch V, Sasaki H, Shepherd F, Sougnez C, Spitz M R, Tsao M S, Twomey D, Verhaak R G, Weinstock G M, Wheeler D A, Winckler W, Yoshizawa A, Yu S, Zakowski M F, Zhang Q, Beer D G, Wistuba I I, Watson M A, Garraway L A, Ladanyi M, Travis W D, Pao W, Rubin M A, Gabriel S B, Gibbs R A, Varmus H E, Wilson R K, Lander E S, Meyerson M (2007). Characterizing the cancer genome in lung adenocarcinoma. Nature, 450(7171): 893-898

DOI PMID

85
Wrage M, Ruosaari S, Eijk P P, Kaifi J T, Hollmén J, Yekebas E F, Izbicki J R, Brakenhoff R H, Streichert T, Riethdorf S, Glatzel M, Ylstra B, Pantel K, Wikman H (2009). Genomic profiles associated with early micrometastasis in lung cancer: relevance of 4q deletion. Clin Cancer Res, 15(5): 1566-1574

DOI PMID

86
Wu X, Ye Y, Rosell R, Amos C I, Stewart D J, Hildebrandt M A, Roth J A, Minna J D, Gu J, Lin J, Buch S C, Nukui T, Ramirez Serrano J L, Taron M, Cassidy A, Lu C, Chang J Y, Lippman S M, Hong W K, Spitz M R, Romkes M, Yang P (2011). Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy. J Natl Cancer Inst, 103(10): 817-825

DOI PMID

87
Yamashita J, Matsuo A, Kurusu Y, Saishoji T, Hayashi N, Ogawa M (2002). Preoperative evidence of circulating tumor cells by means of reverse transcriptase-polymerase chain reaction for carcinoembryonic antigen messenger RNA is an independent predictor of survival in non-small cell lung cancer: a prospective study. J Thorac Cardiovasc Surg, 124(2): 299-305

DOI PMID

88
Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens R M, Okamoto A, Yokota J, Tanaka T, Calin G A, Liu C G, Croce C M, Harris C C (2006). Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell, 9(3): 189-198

DOI PMID

89
Yao N S, Wu Y Y, Janckila A J, Ku C H, Hsieh A T, Ho C L, Lee S H, Chao T Y (2011). Serum tartrate-resistant acid phosphatase 5b (TRACP5b) activity as a biomarker for bone metastasis in non-small cell lung cancer patients. Clin Chim Acta, 412(1-2): 181-185

DOI PMID

90
Yoon K A, Park J H, Han J, Park S, Lee G K, Han J Y, Zo J I, Kim J, Lee J E, Takahashi A, Kubo M, Nakamura Y, Lee J S (2010). A genome-wide association study reveals susceptibility variants for non-small cell lung cancer in the Korean population. Hum Mol Genet, 19(24): 4948-4954

DOI PMID

91
Yu S L, Chen H Y, Chang G C, Chen C Y, Chen H W, Singh S, Cheng C L, Yu C J, Lee Y C, Chen H S, Su T J, Chiang C C, Li H N, Hong Q S, Su H Y, Chen C C, Chen W J, Liu C C, Chan W K, Chen W J, Li K C, Chen J J, Yang P C (2008). MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell, 13(1): 48-57

DOI PMID

92
Zeng X, Hood B L, Sun M, Conrads T P, Day R S, Weissfeld J L, Siegfried J M, Bigbee W L (2010). Lung cancer serum biomarker discovery using glycoprotein capture and liquid chromatography mass spectrometry. J Proteome Res, 9(12): 6440-6449

DOI PMID

93
Zeng X, Hood BL, Zhao T, Conrads TP, Sun M, Gopalakrishnan V, Grover H, Day RS, Weissfeld JL, Wilson DO, Siegfried JM, Bigbee WL(2011). Lung cancer serum biomarker discovery using label-free liquid chromatography-tandem mass spectrometry. J Thorac Oncol, 6(4): 725-734

Outlines

/